The Balloon Array for RBSP Relativistic Electron Losses (BARREL)

BARREL is a multiple-balloon investigation designed to study electron losses from Earth’s Radiation Belts. Selected as a NASA Living with a Star Mission of Opportunity, BARREL augments the Radiation Belt Storm Probes mission by providing measurements of relativistic electron precipitation with a pair of Antarctic balloon campaigns that will be conducted during the Austral summers (January-February) of 2013 and 2014. During each campaign, a total of 20 small (∼20 kg) stratospheric balloons will be successively launched to maintain an array of ∼5 payloads spread across ∼6 hours of magnetic local time in the region that magnetically maps to the radiation belts. Each balloon carries an X-ray spectrometer to measure the bremsstrahlung X-rays produced by precipitating relativistic electrons as they collide with neutrals in the atmosphere, and a DC magnetometer to measure ULF-timescale variations of the magnetic field. BARREL will provide the first balloon measurements of relativistic electron precipitation while comprehensive in situ measurements of both plasma waves and energetic particles are available, and will characterize the spatial scale of precipitation at relativistic energies. All data and analysis software will be made freely available to the scientific community

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.

Remdesivir is efficacious for severe coronavirus disease 2019 (COVID-19) in adults, but data in pregnant women are limited. We describe outcomes in the first 86 pregnant women with severe COVID-19 who were treated with remdesivir. The reported data span 21 March to 16 June 2020 for hospitalized pregnant women with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection and room air oxygen saturation ≤94% whose clinicians requested remdesivir through the compassionate use program. The intended remdesivir treatment course was 10 days (200 mg on day 1, followed by 100 mg for days 2-10, given intravenously). Nineteen of 86 women delivered before their first dose and were reclassified as immediate "postpartum" (median postpartum day 1 [range, 0-3]). At baseline, 40% of pregnant women (median gestational age, 28 weeks) required invasive ventilation, in contrast to 95% of postpartum women (median gestational age at delivery 30 weeks). By day 28 of follow-up, the level of oxygen requirement decreased in 96% and 89% of pregnant and postpartum women, respectively. Among pregnant women, 93% of those on mechanical ventilation were extubated, 93% recovered, and 90% were discharged. Among postpartum women, 89% were extubated, 89% recovered, and 84% were discharged. Remdesivir was well tolerated, with a low incidence of serious adverse events (AEs) (16%). Most AEs were related to pregnancy and underlying disease; most laboratory abnormalities were grade 1 or 2. There was 1 maternal death attributed to underlying disease and no neonatal deaths. Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate-use remdesivir, recovery rates were high, with a low rate of serious AEs